Predicting disease progression in progressive supranuclear palsy in multicenter clinical trials.

about

Poor caregiver mental health predicts mortality of patients with neurodegenerative disease.Mild Cognitive Impairment and Progression to Dementia in Progressive Supranuclear Palsy.

P2860

Q46083852-86AF13A5-0381-4D75-A741-806FF93F71A8 Q50206057-989BE4CD-CA82-46B6-9500-24A463468536

P2860

Predicting disease progression in progressive supranuclear palsy in multicenter clinical trials.

Item

http://www.wikidata.org/entity/Q39771450

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Predicting disease progression ...... n multicenter clinical trials.

@en

Predicting disease progression ...... n multicenter clinical trials.

@nl

type

Item

label

Predicting disease progression ...... n multicenter clinical trials.

@en

Predicting disease progression ...... n multicenter clinical trials.

@nl

prefLabel

Predicting disease progression ...... n multicenter clinical trials.

@en

Predicting disease progression ...... n multicenter clinical trials.

@nl

P1476

Predicting disease progression ...... n multicenter clinical trials.

@en

P2093

AL-108-231 Investigators

http://www.w3.org/2001/XMLSchema#string

Bruce H Morimoto

http://www.w3.org/2001/XMLSchema#string

Iryna V Lobach

http://www.w3.org/2001/XMLSchema#string

Jee Bang

http://www.w3.org/2001/XMLSchema#string

Lon S Schneider

http://www.w3.org/2001/XMLSchema#string

Michael Gold

http://www.w3.org/2001/XMLSchema#string

Rachelle S Doody

http://www.w3.org/2001/XMLSchema#string

P2860

Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study

Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges

Disease severity and progression in progressive supranuclear palsy and multiple system atrophy: validation of the NNIPPS--Parkinson Plus Scale

Development and validation of a geriatric depression screening scale: a preliminary report

Cognitive impairment in patients with multiple system atrophy and progressive supranuclear palsy.

Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial

The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity.

Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop.

Rates of brain atrophy and clinical decline over 6 and 12-month intervals in PSP: determining sample size for treatment trials.

Executive dysfunction is the primary cognitive impairment in progressive supranuclear palsy.

P304

41-48

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.PARKRELDIS.2016.04.014

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2016-04-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27172829

http://www.w3.org/2001/XMLSchema#string

P921

multicenter trial

P932

4914418

http://www.w3.org/2001/XMLSchema#string

Predicting disease progression in progressive supranuclear palsy in multicenter clinical trials.

about

P2860

P2860

Predicting disease progression in progressive supranuclear palsy in multicenter clinical trials.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P50

P577

P698

P921

P932